BALTIMORE - New data demonstrate that BP can be successfully managed in most adolescents who have essential hypertension.

ROME—Aliskiren, an oral direct renin inhibitor, lowers BP more effectively than hydrochlorothiazide as monotherapy or with add-on amlodipine in obese patients with hypertension, according to results reported here at the 44th annual meeting of the European Association for the Study of Diabetes.

STOCKHOLM - Patients with advanced renal cell carcinoma (RCC) who are treated with RAD001 after failing standard therapy have more than twice the progression-free survival (PFS) as placebo-treated patients, new data show.

Oral medication prolongs progression-free survival in patients who have failed conventional treatment.

STOCKHOLM—Treatment with zoledronic acid for two years in men who are undergoing androgen deprivation therapy (ADT) for prostate cancer is usually well tolerated and effective for preventing bone loss, new findings suggest.

STOCKHOLM—Sunitinib used in tandem with docetaxel and prednisone appears to be safe and well tolerated in men with metastatic hormone-refractory prostate cancer (HRPC), investigators announced here at the 33rd Congress of the European Society of Medical Oncology.

SAN FRANCISCO—The investigational agent saxagliptin, which belongs to a new class of anti-diabetic drugs that is taken orally rather than by injection, is effective and safe in treatment-naïve, type 2 diabetics with inadequate glycemic control, new findings suggest.

SAN FRANCISCO—Heavy consumption of artificially sweetened beverages was associated with almost twice the risk of diabetes in a long-term, community-based prospective study, researchers reported here at the American Diabetes Association annual meeting.

PARIS—Older women undergoing surgery for stress urinary incontinence (SUI) fare as well as younger women with respect to perioperative results, but they experience worse two-year outcomes, researchers reported here during a poster session at the Fourth International Consultation on Incontinence.

SAN FRANCISCO—Dietary salt supplementation may reduce the antihypertensive effects of the angiotensin receptor blocker (ARB) telmisartan in patients with type 2 diabetes and hypertension, investigators reported at the 68th Scientific Sessions of the American Diabetes Association. The effect is independent of habitual sodium dietary status.